0001209191-21-007946.txt : 20210204 0001209191-21-007946.hdr.sgml : 20210204 20210204204453 ACCESSION NUMBER: 0001209191-21-007946 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210203 FILED AS OF DATE: 20210204 DATE AS OF CHANGE: 20210204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wilson Mark Andrew CENTRAL INDEX KEY: 0001808356 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 21593004 MAIL ADDRESS: STREET 1: 1613 RAY DRIVE CITY: BURLINGAME STATE: CA ZIP: 94010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-03 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001808356 Wilson Mark Andrew C/O NEKTAR THERAPEUTICS 455 MISSION BAY BLVD SOUTH, SUITE 100 SAN FRANCISCO CA 94158 0 1 0 0 SVP & General Counsel Common Stock 2021-02-03 4 M 0 5344 8.80 D 84244 D Common Stock 2021-02-03 4 S 0 5344 19.45 D 78900 D Stock Option 8.80 2021-02-03 4 M 0 5344 0.00 D 2017-02-06 2021-02-05 Common Stock 5344 0 D This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This number includes 3,107 shares held by the reporting person in his account under the Issuer's ESPP Plan. The acquisition of these shares under that plan is exempt under Rule 16b-3(c). This transaction was executed in multiple trades at prices ranging from $19.30 to $19.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Mark A. Wilson 2021-02-04